Nipple-sparing mastectomy (NSM) – an increasingly popular option for women undergoing treatment for breast cancer – not only achieves good cosmetic outcomes, but also low long-term risk of recurrent breast cancer, reports a study in the October issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). The journal is published in the Lippincott portfolio by Wolters Kluwer.
One in eight women will be diagnosed with breast cancer in her lifetime. For those with BRCA1 and BRCA2 gene mutations, the chances are even higher. The National Breast Cancer Foundation estimates that 55 to 65% of women with the BRCA1 mutation, and 45%…
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include an investigation into the efficacy of dexamethasone for dyspnea relief, a combination therapy for hairy cell leukemia, an analysis of RAS mutations and their prognostic value in acute myeloid leukemia (AML), a possible new combination therapy for basal-like breast cancer, and swallowing exercises to improve the quality of life for patients with head and neck cancer undergoing radiotherapy.
Populations in U.S. counties defined as more vulnerable based on social factors including socioeconomic status and racial/ethnic minority status were significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to research from UTHealth Houston.
Susan G. Komen®, the world’s leading breast cancer organization, is expanding its screening and diagnostics program from nine cities to 12. Now, income-eligible residents from Dallas, Los Angeles, and Memphis also can access no-cost, breast cancer screening and diagnostic services. Atlanta, Chicago, Fort Worth, Houston, Madison, WI, Marshfield, WI, Philadelphia, Virginia Beach, and Washington D.C. are the other cities where the program is already operating.
Fat cells, or adipocytes, that grow in close proximity to breast cancers can shift into other cell types that promote tumor growth, a new study by UT Southwestern researchers suggests. The findings, published in Cell Reports, could lead to new ways to fight breast cancer, a disease that is diagnosed in more than 300,000 U.S. women each year and kills nearly 45,000 annually.
Scientists from The Tisch Cancer Institute have uncovered a mechanism by which certain breast cancer cells regulate their own metastases, fuel dissemination from the original tumor site, and determine routes to invade distant organs such as the lungs, according to a study published in Cell Reports in September.
A two-pronged approach to imaging breast density in mice, developed by researchers at Georgetown Lombardi Comprehensive Cancer Center, resulted in better detection of changes in breast tissue, including spotting early signs of cancer. The researchers hope that this approach will be translated from mice and improve breast imaging for people; it may also help with prognosis of disease as density can be linked to specific patterns of mammary gland growth, including signs of cancer development.
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.
A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumor-induced immunosuppression.
New method uses nanospheres to measure forces that cancer cells use to spread through tissue
Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open on August 11, 2022.
Project will study the role follicle stimulating hormone plays during menopause and how it contributes to the development of postmenopausal obesity and breast cancer.
Studying a deadly type of breast cancer called triple negative, Johns Hopkins Medicine scientists say they have identified key molecular differences between cancer cells that cling to an initial tumor and those that venture off to form distant tumors.
The National Comprehensive Cancer Network (NCCN) has published new NCCN Guidelines for Patients: Breast Cancer Screening and Diagnosis to help people understand their personal risk for breast cancer, when they should begin screening, and how often to screen—in order to detect cancer earlier, for more treatment options and better outcomes.
Telling a child about their mother’s risk of hereditary breast and ovarian cancer does not adversely influence the offspring’s lifestyle or quality of life in the long term, according to a new study led by researchers at Georgetown Lombardi Comprehensive Cancer Center.
A new paper in the Journal of the National Cancer Institute, published by Oxford University Press, finds that menopausal hormone therapy for breast cancer survivors is not associated with breast cancer reoccurrence, despite worries among some researchers and physicians.
Coral Omene, MD, PhD, medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center together with RWJBarnabas Health, has been awarded a $50,000 grant from the V Foundation for Cancer Research in partnership with ESPN to increase clinical trial awareness and enrollment of Black women with breast cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.
A study that surveyed cancer screening data included in medical journals worldwide from January 2020 into December 2021 showed significant decreases in the number of screenings for breast, colorectal and cervical cancers during the early phase of the Covid-19 pandemic.
Having a baby after breast cancer does not negatively impact a woman’s chance of surviving the disease.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.
Brooke Emerling from Sanford Burnham Prebys has been awarded a new grant from the National Institutes of Health (NIH) to continue her work on cellular signaling in cancer. The four-year, $2.3 million project could accelerate the development of new therapies for a range of cancers, particularly metastatic breast cancer. It also offers an answer to a longstanding mystery in cancer metabolism.
Delivering a targeted immunotoxin into breast ducts via openings in the nipple wiped out all visible and invisible precancerous lesions in laboratory studies, led by researchers at the Johns Hopkins Kimmel Cancer Center, of very early stage breast cancers
Susan G. Komen® is awarding $21.7 million to fund 48 new research projects at 26 distinguished academic medical institutions in the U.S. that are focused on improving patient outcomes – particularly for people with the most aggressive breast cancers, or who have experienced a recurrence or metastasis.
Médica Sur, the first international member of the Mayo Clinic Care Network, and Mayo Clinic will deepen their relationship by working together to advance cancer care at Médica Sur. The new collaboration will begin July 1.
New population study in JNCCN on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.
A new perspective by researchers from the American Cancer Society and the University of Texas Health Science Center at San Antonio shows the high burden of breast cancer mortality in African American (Black) women versus White women began in the United States in the 1980’s.
Researchers from Wake Forest University School of Medicine have discovered a possible new approach in treating solid tumors through the creation of a novel nanoparticle.
Research shows that what we eat can influence our cancer risk, but it’s not always clear which foods or dietary patterns are best for cancer prevention. Results from a new study suggest that the quality or overall healthiness of a person’s diet may be key.
Chemicals called parabens, which are found in widely used hair and personal care products, cause harmful effects in breast cancer cells from Black women, according to a new study being presented Sunday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Probiotic bacteria may enhance anti-cancer activities of the breast cancer drug tamoxifen and other endocrine-targeted therapies, which could help reduce the risk of estrogen receptive positive (ER+) breast cancer, suggests a new study presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a new study presented Sunday, June 12 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
A new genetic study discovered that not all breast cancers that develop after DCIS arise from the original DCIS lesion. Roughly 1 in 5 are new cancers, genetically unrelated to the original DCIS.
According to a new study, use of breast imaging services – including mammography screening – may remain at only 85.3% of pre-pandemic utilization.
McMaster researchers tracked 501 patients with luminal A breast cancer for five years post-surgery and found the recurrence of cancer in the breast was just 2.3 per cent without radiotherapy. This was roughly comparable with a 1.9 per cent risk this patient sample had of developing a new breast cancer in their other untreated breast.
A compound synthesized by a team led by UT Southwestern scientists kills a range of hard-to-treat cancer types by targeting a previously unexploited vulnerability, a new study reports. The findings, published in Nature Cancer, could eventually lead to new drugs to fight these cancers, which currently have few effective treatments.
Research scientists and statisticians from UC San Francisco have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.
UC San Diego researchers discover mechanism linking breast cancer and diabetes, each of which promotes development and growth of the other.
A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease, according to new findings.
Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.
Older breast cancer survivors with cardiometabolic risk factors who restricted food intake to eight hours during the weekday, followed by 16 hours of fasting, lowered their risk of cardiovascular disease (CVD) after a few weeks, according to a new research letter publishing today in JACC: CardioOncology
The risk of invasive breast cancer in men may be associated with self-reported infertility in the male partner finds a study published in the open-access journal Breast Cancer Research.
Research from the University of Michigan Rogel Cancer Center could provide a new approach to treating an aggressive form of breast cancer. A study led by Duxin Sun, Ph.D., found that targeting the immune microenvironment in lymph nodes and tumors simultaneously led to long-term tumor remission in mice models of metastatic triple negative breast cancer.
In a new study published in the journal Cell Reports, Moffitt Cancer Center researchers show that cancer cells in an acidic environment undergo lipid synthesis and accumulation. The team identified the key signaling molecules responsible for these changes and discovered that these alterations are associated with poor outcomes and disease progression among breast cancer patients.
Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.
When you’re a breast cancer survivor, the last thing you need is another health scare. So, it’s concerning to know that up to 48 per cent of breast cancer patients will go on to fight heart disease as a direct result of chemotherapy.
Women with multiple sclerosis (MS) are less likely to have breast cancers detected through cancer screenings than women without MS, according to new research published in the April 27, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. Conversely, researchers also found that people with MS are more likely to have colorectal cancers detected at an early stage than those without MS.